Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Atypon full text link Atypon Free PMC article
Full text links

Actions

.2000 Jun 20;97(13):7500-2.
doi: 10.1073/pnas.130155097.

St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor

Affiliations

St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor

L B Moore et al. Proc Natl Acad Sci U S A..

Abstract

St. John's wort (Hypericum perforatum) is an herbal remedy used widely for the treatment of depression. Recent clinical studies demonstrate that hypericum extracts increase the metabolism of various drugs, including combined oral contraceptives, cyclosporin, and indinavir. In this report, we show that hyperforin, a constituent of St. John's wort with antidepressant activity, is a potent ligand (K(i) = 27 nM) for the pregnane X receptor, an orphan nuclear receptor that regulates expression of the cytochrome P450 (CYP) 3A4 monooxygenase. Treatment of primary human hepatocytes with hypericum extracts or hyperforin results in a marked induction of CYP3A4 expression. Because CYP3A4 is involved in the oxidative metabolism of >50% of all drugs, our findings provide a molecular mechanism for the interaction of St. John's wort with drugs and suggest that hypericum extracts are likely to interact with many more drugs than previously had been realized.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hyperforin is a potent activator of PXR. (A) CV-1 cells were transfected with expression plasmids for human PXR and the (CYP3A1)2-tk-CAT reporter. Cells were treated with extracts prepared from three different commercial preparations of St. John's wort [extract 1, Nature's Way (9 μg/ml); extract 2, Nature's Plus (75 μg/ml); extract 3, Solaray (7 μg/ml)] or with 10 μM of the indicated pure compounds, except for hyperforin, which was tested at 1 μM. Hyperforin was toxic to cells at concentrations >1 μM. Cell extracts subsequently were assayed for CAT activity. Data represent the mean of assays performed in quadruplicate ± SE and are plotted as -fold activation relative to transfected cells treated with vehicle alone. (B) Chemical structure of hyperforin. (C) CV-1 cells were transfected as inA and treated with increasing concentrations of hyperforin (squares) or rifampicin (circles). Data points represent the mean of assays performed in triplicate.
Figure 2
Figure 2
Hyperforin binds to PXR with high affinity. Competition binding assays were performed with purified human PXR LBD and 10 nM of the high-affinity PXR radioligand [3H]SR12813 in the presence of the indicated concentrations of hyperforin (squares), SR12813 (circles), or umbelliferone (triangles). Each data point represents the mean of assays performed in triplicate. TheKi value of hyperforin was calculated to be 27 nM by nonlinear regression analysis.
Figure 3
Figure 3
St. John's wort extracts and hyperforin induceCYP3A4 expression in human hepatocytes. Northern blot analysis was performed with total RNA (10 μg) prepared from primary cultures of human hepatocytes treated for 30 h with extracts prepared from three different commercial preparations of St. John's wort [extract 1, Nature's Way (9 μg/ml); extract 2, Nature's Plus (75 μg/ml); extract 3, Solaray (7 μg/ml)], 1 μM hyperforin, or vehicle alone (0.1% ethanol). The blot was probed sequentially with32P-labeled fragments of CYP3A4 and β-actin.
See this image and copyright information in PMC

References

    1. Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. Br Med J. 1996;313:253–258. - PMC - PubMed
    1. Volz H P. Pharmacopsychiatry. 1997;2:72–76. - PubMed
    1. Wheatley D. Pharmacopsychiatry. 1997;2:77–80. - PubMed
    1. Bhattacharya S K, Chakrabarti A, Chatterjee S S. Pharmacopsychiatry. 1998;1:22–29. - PubMed
    1. Butterweck V, Wall A, Lieflander-Wulf U, Winterhoff H, Nahrstedt A. Pharmacopsychiatry. 1997;2:117–124. - PubMed

MeSH terms

Substances

LinkOut - more resources

Full text links
Atypon full text link Atypon Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp